Literature DB >> 1907592

Increased incidence of euthyroid and hyperthyroid goiters independently of thyrotropin in patients with acromegaly.

C Wüster1, G Steger, A Schmelzle, J Gottswinter, H W Minne, R Ziegler.   

Abstract

The incidence of palpable goiters, the thyroid functional state and thyroid radioisotope uptake was analyzed retrospectively in 80 patients with acromegaly and 80 patients with prolactinomas. 71% of all patients with acromegaly had an enlargement of the thyroid (goiter); 49% of them had diffuse and 39% nodular goiters. The incidence of goiters in patients with prolactinomas from the same iodine deficient geographic region was only 35% (82% diffuse and 18% nodular). 17.5% of acromegalic patients underwent thyroid surgery before diagnosis of growth hormone excess. 17.5% of acromegalic patients with goiters had autonomous areas in their thyroids and 5% were clearly hyperthyroid. Goiters developed slightly more often in females (74%) than in males (67%). The mean preoperative growth hormone level was higher in acromegalic patients with goiter. The incidence of goiters was positively correlated with the documented time of elevated growth hormone concentration in serum. Two patients with exaggerated response of thyrotropin (TSH) (delta TSH greater than 20 mU/l) to the application of thyrotropin-releasing hormone (TRH) had no goiters. On the other hand most patients (61%) with goiters had a low TSH-response to TRH (delta TSH less than 10 mU/l) representing in part occult autonomy of thyroid function. No patient with prolactinoma has had previous thyroid surgery nor thyroid autonomy. One patient with prolactinoma suffered from Graves' disease and none of the acromegalic patients had this disease. We finally conclude that the elevation of growth hormone leads to increased incidence of euthyroid and hyperthyroid (autonomous) goiters independently of the influence of TSH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907592     DOI: 10.1055/s-2007-1003632

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  12 in total

1.  Acromegaly and thyroid.

Authors:  Klaus von Werder
Journal:  J Endocrinol Invest       Date:  2002-12       Impact factor: 4.256

Review 2.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

3.  Thyroid volume and function in patients with acromegaly living in iodine deficient areas.

Authors:  R Junik; J Sawicka; W Kozak; M Gembicki
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

4.  Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study.

Authors:  M Gasperi; E Martino; L Manetti; M Arosio; S Porretti; G Faglia; S Mariotti; A M Colao; G Lombardi; R Baldelli; F Camanni; A Liuzzi
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

5.  Circadian profile of serum melatonin in patients with Cushing's syndrome or acromegaly.

Authors:  M Terzolo; A Piovesan; A Alì; A Codegone; A Pia; G Reimondo; M Torta; P Paccotti; G Borretta; A Angeli
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

Review 6.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

7.  Primary treatment of acromegaly with high-dose lanreotide: a case series.

Authors:  Christian Wuster; Stefan Both; Uwe Cordes; Wael Omran; Robert Reisch
Journal:  J Med Case Rep       Date:  2010-03-08

8.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

Review 9.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

Review 10.  Insulin-Like Growth Factor Pathway and the Thyroid.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.